

Checklist for BRIUMVI (ublituximab) Referral

Patient	t Name:		_ DOB:	Date:						
Referri	ng Phys	sician:		NPI:						
Office (Office Contact/Title/Email:									
Office Address:										
Office I	Phone: _.		Office Fax:							
Best contact number for physician in case of reaction:										
Please return completed checklist and checklist items to initiate referral. Use this form as fax cover sheet.										
	Patient demographic information									
	Insurar	surance information and copy of insurance card/s (front and back). *Include primary and secondary insurance								
	Suppor	orting clinical notes and office visits. Two notes preferred.								
	0	Note should include any therapies tried/failed, and must include discussion about Briumvi								
	0	Medication list and allergies Last Briumvi or Ocrevus infusion note,	if available							
_	0 0			patitis B screening, and brain MRI within 1 year						
	 For continued therapy: CBC w diff and CMP prior to each infusion 									
	0		•	t. Live vaccines should be given at least 4 weeks						
		prior to treatment, and non-live vaccin		•						
☐ Briumvi Prescribing Order (see attached)										
We will obtain prior authorization and schedule your patient as soon as possible –										
Fax all information to our Infusion Coordinator: 508-698-8671										

Visit our website: www.InfusionCenterNE.com
Email: info@infusioncenterne.com

Call with any questions: 781-551-5812 ext. 112



Prescribing Order: BRIUMVI (ublituximab)

Date of Order:		r:	New StartMaintenalDate of last				nce st infusion:		
Patient Name:			DOB:				M/F:		
Dia	ignosis (in	clude ICD-10 code/s):							
	NKDA	Allergies:							
Pat	ient Weig	ht:							
Pre	emedication	on:							
	Acetamir	nophen 1000mg PO		Diph	enhy	dramine 25mg IV			
	Loratadir	ne 10mg or Cetirizine 10mg PO		Solu-	med	irol 125mg IV in 50ml ov	er 15min		
	Diphenhy	ydramine 25mg PO		Othe	r:				
Lak	Orders:								
	CBC w/di	ff, CMP every weeks		Othe	er:				
<u>Bri</u>	 Briumvi 150mg/250ml NS IV for first infusion. Administer over 4 hours: start infusion at 10ml/hr for fir 30min, increase to 20ml/hr for 30 min, increase to 35ml/hr for 60 min, then 100ml/hr for remaining hours. Briumvi 450mg/250ml NS IV for second infusion (2 weeks after first infusion) and then subseque infusions every 6 months. Administer over 1 hour: start infusion at 100ml/hr for the first 30min, the increase to 400ml/hr for the remaining 30min. 								
		Post infusion observation: Required for NS 100ml/hr x 1 hour	or 1 hour after Brit	umvi's	first	two infusions			
Ad	ministrati	on:							
	✓ \	/ital Signs: Pre-treatment, at every ra	ate change, and po	st-tre	atme	ent			
	✓ Do not administer if patient has signs or symptoms of active infection								
	√	n case of infusion reaction, STOP infu	usion and follow IC	NE inf	usio	n reaction protocol. Not	tify physician.		
Ordering Provider Name		NPI							
Sig	nature				Date				